Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- Improving Healthcare Outcomes through IT Policy
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
- Veterans in Private Sector: Making the Transition
Shows & Panels
FDA finds contamination concerns at Ameridose
Monday - 11/12/2012, 4:17pm EST
WASHINGTON (AP) - Federal health inspectors have found more than a dozen sterility problems, including insects, at a drugmaking facility with the same founders as the specialty pharmacy linked to a deadly meningitis outbreak.
The Food and Drug Administration has released the results of a monthlong inspection of Ameridose, a Westborough, Mass.-based company that makes a variety of injectable drugs.
Inspectors say they found insects within 10 feet of a supposedly sterile area where drugs are manufactured. In another case, inspectors reported a bird flying into a room where drugs are stored.
Ameridose agreed to shut down for inspection in October after tainted steroids from its sister company, the New England Compounding Center, were linked to a fungal meningitis outbreak that's spread to 19 states and caused 32 deaths.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)